Search Results - "Doshi, Parul"

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort by Papillon-Cavanagh, Simon, Doshi, Parul, Dobrin, Radu, Szustakowski, Joseph, Walsh, Alice M

“…IntroductionSomatic mutations in STK11 and KEAP1, frequently comutated in non-squamous non-small cell lung cancer (NSQ NSCLC), have been associated with poor…”
Get full text

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 by Owonikoko, Taofeek K, Park, Keunchil, Govindan, Ramaswamy, Ready, Neal, Reck, Martin, Peters, Solange, Dakhil, Shaker R, Navarro, Alejandro, Rodríguez-Cid, Jerónimo, Schenker, Michael, Lee, Jong-Seok, Gutierrez, Vanesa, Percent, Ivor, Morgensztern, Daniel, Barrios, Carlos H, Greillier, Laurent, Baka, Sofia, Patel, Miten, Lin, Wen Hong, Selvaggi, Giovanni, Baudelet, Christine, Baden, Jonathan, Pandya, Dimple, Doshi, Parul, Kim, Hye Ryun

“…In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability…”
Get full text

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy by Oostendorp, Marlies, Lammerts van Bueren, Jeroen J., Doshi, Parul, Khan, Imran, Ahmadi, Tahamtan, Parren, Paul W.H.I., van Solinge, Wouter W., De Vooght, Karen M.K.

“…BACKGROUND Monoclonal antibodies (MoAbs) are increasingly integrated in the standard of care. The notion that therapeutic MoAbs can interfere with clinical…”
Get full text

Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer by Song, Lanxi, Smith, Matthew A, Doshi, Parul, Sasser, Kate, Fulp, William, Altiok, Soner, Haura, Eric B

“…Interleukin-6 (IL-6) can activate downstream signaling pathways in lung cancer cells, such as the STAT3 pathway, and is reported to be produced by tumor cells…”
Get more information

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens by Vidal-Crespo, Anna, Matas-Céspedes, Alba, Rodriguez, Vanina, Rossi, Cédric, Valero, Juan G, Serrat, Neus, Sanjuan-Pla, Alejandra, Menéndez, Pablo, Roué, Gaël, López-Guillermo, Armando, Giné, Eva, Campo, Elías, Colomer, Dolors, Bezombes, Christine, van Bueren, Jeroen Lammerts, Chiu, Christopher, Doshi, Parul, Pérez-Galán, Patricia

“…CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a…”
Get full text

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages by Kersten, Kelly, Coffelt, Seth B., Hoogstraat, Marlous, Verstegen, Niels J.M., Vrijland, Kim, Ciampricotti, Metamia, Doornebal, Chris W., Hau, Cheei-Sing, Wellenstein, Max D., Salvagno, Camilla, Doshi, Parul, Lips, Esther H., Wessels, Lodewyk F.A., de Visser, Karin E.

“…Patients with primary solid malignancies frequently exhibit signs of systemic inflammation. Notably, elevated levels of neutrophils and their associated…”
Get full text

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia by Matas-Céspedes, Alba, Vidal-Crespo, Anna, Rodriguez, Vanina, Villamor, Neus, Delgado, Julio, Giné, Eva, Roca-Ho, Heleia, Menéndez, Pablo, Campo, Elías, López-Guillermo, Armando, Colomer, Dolors, Roué, Gaël, Wiestner, Adrian, Parren, Paul W H I, Doshi, Parul, van Bueren, Jeroen Lammerts, Pérez-Galán, Patricia

“…To establish a proof-of-concept for the efficacy of the anti-CD38 antibody daratumumab in the poor prognosis CD38 chronic lymphocytic leukemia (CLL) subtype…”
Get full text

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB by He, Jie, Kalinava, Natallia, Doshi, Parul, Pavlick, Dean C, Albacker, Lee A, Ebot, Ericka M, Tukachinsky, Hanna, Pratt, James, Fusaro, Gina, Oxnard, Geoffrey R, Green, George, Fabrizio, David, Baden, Jonathan

“…BackgroundAn accumulation of somatic mutations in tumors leads to increased neoantigen levels and antitumor immune response. Tumor mutational burden (TMB)…”
Get full text

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance by de Haart, Sanne J, Holthof, Lisa, Noort, Willy A, Minnema, Monique C, Emmelot, Maarten E, Aarts-Riemens, Tineke, Doshi, Parul, Sasser, Kate, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C M, van de Donk, Niels W C J, Lokhorst, Henk M, Groen, Richard W J, Mutis, Tuna

Get full text

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden by Schenker, Michael, Burotto, Mauricio, Richardet, Martin, Ciuleanu, Tudor-Eliade, Gonçalves, Anthony, Steeghs, Neeltje, Schoffski, Patrick, Ascierto, Paolo A, Maio, Michele, Lugowska, Iwona, Lupinacci, Lorena, Leary, Alexandra, Delord, Jean-Pierre, Grasselli, Julieta, Tan, David S P, Friedmann, Jennifer, Vuky, Jacqueline, Tschaika, Marina, Konduru, Somasekhar, Vemula, Sai Vikram, Slepetis, Ruta, Kollia, Georgia, Pacius, Misena, Duong, Quyen, Huang, Ning, Doshi, Parul, Baden, Jonathan, Di Nicola, Massimo

“…BackgroundCheckpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive…”
Get full text

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth by Ma, Xun, Wong, Sandy W, Zhou, Ping, Chaulagain, Chakra P, Doshi, Parul, Klein, Andreas K, Sprague, Kellie, Kugelmass, Adin, Toskic, Denis, Warner, Melissa, Miller, Kenneth B, Lee, Lisa, Varga, Cindy, Comenzo, Raymond L

“…The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells…”
Get full text

Resolving the daratumumab interference with blood compatibility testing by Chapuy, Claudia I., Nicholson, Rachel T., Aguad, Maria D., Chapuy, Bjoern, Laubach, Jacob P., Richardson, Paul G., Doshi, Parul, Kaufman, Richard M.

“…BACKGROUND Daratumumab (DARA), a promising novel therapy for multiple myeloma, is an IgG1κ monoclonal antibody that recognizes CD38 on myeloma cells. During…”
Get full text

Abstract 2047: Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer by Balli, David, Wang, Xuya, Rizvi, Naiyer A., Chan, Timothy A., Dowlati, Afshin, Doshi, Parul, Chang, Han

“…Abstract Background: Anti–programmed death-1/programmed death ligand 1 inhibitors have been approved for the treatment of advanced small cell lung cancer…”
Get full text

International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing by Chapuy, Claudia I., Aguad, Maria D., Nicholson, Rachel T., AuBuchon, James P., Cohn, Claudia S., Delaney, Meghan, Fung, Mark K., Unger, Meredith, Doshi, Parul, Murphy, Michael F., Dumont, Larry J., Kaufman, Richard M.

“…BACKGROUND Daratumumab (DARA) consistently interferes with routine blood bank serologic testing by directly binding to CD38 expressed on reagent red blood…”
Get full text

Abstract 3221: T-cell receptor sequencing for pharmacodynamic and response biomarkers of checkpoint blockade by Papillon-Cavanagh, Simon, Walsh, Alice M., Qi, Zhenhao, Wind-Rotolo, Megan, Saci, Abdel, Doshi, Parul, Dobrin, Radu, Szustakowski, Joseph

“…Abstract Background: Immunomodulatory cancer drugs such as anti-programmed death 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) antibodies have…”
Get full text

Transfusion management in the era of magrolimab (Hu5F9‐G4), an anti‐CD47 monoclonal antibody therapy by Singh, Nirupama, Staves, Julie, Storry, Jill R., Dinoso, Jason, Renard, Camille, Doshi, Parul, Johnson, Lisa D.S., Westhoff, Connie M., Murphy, Michael F.

Get full text

Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells by Saleh, Oussama A, Blalock, William L, Burrows, Carla, Steelman, Linda S, Doshi, Parul D, McKearn, John P, McCubrey, James A

“…Repopulating hematopoietic cell compartments after myeloablative chemotherapy remains a key factor in a successful chemotherapy program. Modified and chimeric…”
Get more information

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers by Moisan, Francois, Francisco, Edgar B., Brozovic, Anamaria, Duran, George E., Wang, Yan C., Chaturvedi, Shalini, Seetharam, Shobha, Snyder, Linda A., Doshi, Parul, Sikic, Branimir I.

“…Ovarian cancer is associated with a leukocyte infiltrate and high levels of chemokines such as CCL2. We tested the hypothesis that CCL2 inhibition can enhance…”
Get full text

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma by Chari, Ajai, Arinsburg, Suzanne, Jagannath, Sundar, Satta, Toshihisa, Treadwell, Ivey, Catamero, Donna, Morgan, Gillian, Feng, Huaibao, Uhlar, Clarissa, Khan, Imran, Doshi, Parul, Usmani, Saad

“…Daratumumab binds CD38 on red blood cells (RBCs), resulting in panagglutination in blood compatibility tests. RBC transfusions and transfusion-related adverse…”
Get full text

Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study by Chari, Ajai, Usmani, Saad Z, Krishnan, Amrita, Lonial, Sagar, Comenzo, Raymond, Wu, Kaida, Wang, Jianping, Doshi, Parul, Weiss, Brendan M, Schecter, Jordan, Jakubowiak, Andrzej J.

“…Introduction: Standard of care treatments for patients (pts) with newly diagnosed multiple myeloma (NDMM) include triplet regimens containing a proteasome…”
Get full text